P. Rottoli (Siena, Italy), C. Ravaglia (Castelbolognese, Italy)
Cognitive failure in sarcoidosis
M. Omcikus, V. Vucinic, S. Filipovic, J. Videnovic (Belgrade, Republic Of Serbia)
|   |
Comorbidities associated with sarcoidosis – Results from long-term observational study
A. Nowinski, E. Puscinska, A. Goljan-Geremek, M. Bednarek, D. Kaminski, D. Gorecka (Warsaw, Poland)
| |
Biomarkers in sarcoidois follow-up: Angiotensin-converting enzyme or chitotriosidase?
M. Harlander, M. Zupancic, B. Salobir, M. Tercelj (Ljubljana, Slovenia)
| |
Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients
V. Kouranos, G. Tzelepis, A. Rapti, S. Mavrogeni, K. Aggeli, E. Manali, A. Kallianos, R. Sharma, G. Filipatos, A. Wells, P. Sfikakis, E. Gialafos (London, United Kingdom; Athens, Greece)
| |
How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study
M. Martusewicz-Boros, P. Boros, E. Wiatr, K. Roszkowski-Sliz (Warsaw, Poland)
| |
Is pulmonary sarcoidosis more severe in children? A multicentric retrospective study
N. Nathan, P. Marcelo, V. Houdouin, R. Epaud, J. de Blic, D. Valeyre, A. Houzel, P. F. Busson, H. Corvol, A. Deschildre, A. Clement, For the RespiRare Group (Paris, Lille, Créteil, Bobigny, Dijon, France)
| |
Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial
K. Hostettler, F. Baty, R. Kleiner, L. Junker, M. Tamm, M. Brutsche (Basel, St. Gallen, Switzerland)
| |
Sarcoidosis related to interferon and ribavirin treatment of hepatitis C – Analysis of four cases
M. Sobiecka, M. Bartosiewicz, K. Lewandowska, P. Radwan-Rohrenschef, I. Bestry, R. Langfort, J. Kus (Warsaw, Poland)
| |
Mortality in sarcoidosis, results from one centre, long term observational study
E. Puscinska, A. Nowinski, A. Goljan-Geremek, M. Bednarek, D. Kaminski, A. Kowalska, D. Gorecka (Warsaw, Poland)
| |
Experience of endobronchial ultrasound - transbronchial needle aspiration (EBUS-TBNA) in granulomatous disease
A. Marshall, L. Ahmed, G. Chalmers (Glasgow, United Kingdom)
| |
Determination of cardiac involvement of sarcoidosis with cardiac MR, ECHO and Holter ECG
M. Tosun, S. Keskin, H. Akilli, M. Kayrak, A. Yesildag, K. Uzun (Konya, Turkey)
| |
Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease
M. Doubkova, M. Karpisek, J. Mazoch, J. Skrickova, M. Doubek (Brno, Czech Republic)
| |
Sarcoidosisandpulmonarydust: Mineralogical analysis (MA) and optical microscopy (OM)
M. Catinon, C. Chemarin, E. Villard, A. S. Blanchet-Legens, S. Vuillermoz-Blas, S. Assaad, C. Cavalin, P. A. Rosental, M. Vincent (Lyon, Paris, France)
| |
Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis
A. Goljan Geremek, M. Bednarek, E. Puscinska, A. Nowinski, A. Kowalska, M. Czystowska, D. Korzybski, D. Górecka (Warsaw, Poland)
| |
Predictors of cardiovascular events in newly diagnosed patients with sarcoidosis
V. Kouranos, A. Rapti, E. Peros, M. Ntouskou, K. Aggeli, E. Manali, S. Papiris, C. Kostopoulos, G. Kaltsakas, N. Koulouris, A. Wells, P. Sfikakis, G. Tzelepis, E. Gialafos (London, United Kingdom; Athens, Greece)
| |
Impact of smoking habit on lung function in a large cohort sarcoidosis patients.
P. Boros, M. Martusewicz-Boros, S. Wesolowski (Warsaw, Poland)
| |